SLITRK5 is a cellular protein whose normal function appears to suppress bone formation and could be a potential new target for the treatment ofosteoporosis, according to a collaborative study conducted by Weill Cornell Medicine and NewYork-Presbyterian researchers.
Cells manifesting the SLITRK5 protein are marked with magenta (left) and a bone-forming osteoblast marker in green (center). These markers were observed in the cancellous bone in the medulla space (top) or on the outer layer covering the bone (bottom). The overlap between these two markers (right) shows that SLITRK5 is found in bone-forming osteoblasts but not in other cell types, helping to make SLITRK5 a target for skeletal disease treatment. Credit: Dr. Matthew Greenblatt and Dr. Jun Sun
There Research was published in the scientific journal Nature Communications.